Clinical Impact of Sub-Clonal RAS/BRAF Alterations in Liquid Biopsies From Patients With Advanced or Metastatic CRC
Consistent with tumor tissue biopsy data, patients with CRC harboring sub-clonal RAS/BRAF mutations as assessed by liquid biopsy may derive benefit from anti-EGFR therapy, warranting further investigation.
Authors
- Zheng Feng (ORCID: https://orcid.org/0000-0003-3858-2205)
- Danyi Wang (ORCID: https://orcid.org/0009-0008-0820-7037)
- Soetkin Vlassak
- Christopher Stroh (ORCID: https://orcid.org/0009-0002-2635-4176)
- Jiemin Liao (ORCID: https://orcid.org/0000-0001-6848-5532)
- Peter Gibbs (ORCID: https://orcid.org/0000-0003-1423-4484)
- Jawad Hamad
- Kathrin Heinrich (ORCID: https://orcid.org/0000-0003-3580-2313)
- Khalid Abubaker
- Juergen Scheuenpflug
- Adnan Khattak (ORCID: https://orcid.org/0009-0008-2954-119X)
Institutions
- Edith Cowan University (AU)
- Merck KGaA, Darmstadt (Germany) (DE)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Fiona Stanley Hospital (AU)
- LMU Klinikum (DE)
- Guardant (United States) (US)
- Ludwig-Maximilians-Universität München (DE)
- Merck Serono S.p.A. (Italy) (IT)
Publication Details
- Journal
- Clinical Colorectal Cancer
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1016/j.clcc.2025.03.004
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Merck KGaA